Core Scientific's colocation revenue surges, but concentration and liquidity risks persist

What happened

Core Scientific reported third-quarter GAAP colocation revenue of $215 million, a nearly 60% sequential increase, signaling a rapid ramp in AI/HPC hosting conversion. The company now guides to $1.8 billion in annual revenue from contracted capacity, a dramatic jump from $319 million total revenue in 2025. This acceleration aligns with management's plan to convert its entire power portfolio to high-density colocation, but it remains heavily dependent on CoreWeave, which accounted for 67% of Q1 2026 revenue. The headline numbers do not address key risks highlighted in the latest 10-Q: unleased customer power capacity expanded to 685 MW, restricted cash requirements are rising, and an uncapped completion guarantee sits behind secured debt. The stock's reaction will depend on whether revenue growth is accompanied by new customer contracts and improved liquidity metrics in the next quarterly filing.

Implication

The $1.8 billion annual revenue target, if realized, would validate the colocation pivot and could push EBITDA positive, but it assumes full deployment of contracted capacity without delays or counterparty issues. The 60% sequential colocation revenue growth is a positive milestone, yet it may still be largely from the CoreWeave framework, leaving concentration risk unresolved. The master report's WAIT rating remains appropriate until the next 10-Q reveals whether leased MW increased above 590 MW and unleased MW declined from 685 MW. Investors should monitor liquidity and restricted cash: if the revenue ramp requires additional collateral postings, the cash conversion cycle may deteriorate despite top-line growth. A break above the $36 trim level with evidence of new signed customers would warrant a rating upgrade, while a stall in billable MW below 400 MW would keep the stock range-bound.

Thesis delta

The previous thesis required leased MW to rise above 590 and concentration to fall; the new revenue guidance suggests contracted capacity may already be sufficient to generate $1.8 billion annual revenue, but it does not confirm diversification. Execution is progressing faster than expected on revenue conversion, but the single-customer concentration and liquidity risks remain. Therefore, the WAIT rating is unchanged, with conviction intact.